NextCell Pharma

"Expansion with three common emerging viruses greatly increases ProTrans'  potential future use case.  There is reason to believe that lung disease is a particularly well-suited area for ProTrans as infused stromal cells are well documented to traffic to the lungs. ProTrans is given to treat a complication, pneumonia, or hyperinflammation of the lung, which manifests in breathing difficulties and injury to the lung irrespective of which virus causes it," says Mathias Svahn, CEO.

ProTrans19+SE is carried out at the University Hospital in Örebro in collaboration with the Division of Clinical Trials and Karolinska Trial Alliance. The Principal Investigator is Associate Professor Josefin Sundh. So far, a total of 5 patients with SARS-CoV-2 infection have  been treated.

Full revised study title is: " Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): a Randomized Phase IB Controlled Clinical Trial", (EudraCT 2020-002078-29). NextCell is sponsoring the study which will include nine patients with severe pneumonia and confirmed viral infection, who are treated with low  dose (3 patients) medium dose (3 patients)  and high dose (3 patients) of ProTrans. 

The study is registered on clinicaltrials.gov with number NCT04896853.